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Introduction
Antitubulin drugs including paclitaxel (Taxol), docetaxel, vinblastine, etc have widely been used for the treatment of a variety of human cancers such as breast and ovarian cancers, non-small cell lung cancer (NSCLC), and head and neck cancer (1) (2) (3) . These drugs can directly bind to β-tubulin and either promote or reduce β-tubulin polymerization, which changes the stability of microtubules (4) . The change in microtubule stability can subsequently exert a mitotic block by altering kinetochore tension which can activates the spindle assembly checkpoint, resulting in mitotic delay and subsequent apoptosis (5) . While antitubulin drugs kill cancer cells and can sometimes effectively suppress tumor growth in cancer patients, a significant proportion of tumors is either intrinsically resistant to antitubulin drugs or later develop resistance after primary therapy, leading to disease relapse and patient mortality, which is a major obstacle to successful cancer treatments (2, 6) . Therefore, identification and characterization of cellular genes or signaling pathways responsible for antitubulin drug resistance is critical for successful treatment of cancers. In addition, although tremendous progress has been made toward identifying the genes involved in antitubulin drug response, surprisingly, the signaling pathways by which antitubulin drugs cause mitotic arrest and cell death are poorly defined.
YAP (Yes-associated protein) and TAZ (Transcriptional co-activator with PDZ binding motif) are paralogs of WW domain-containing transcriptional co-activators, which share 60% similarity and activate many transcriptional factors important for the development of various tissues in mammals (7, 8) . Recently, TAZ and YAP have been identified as oncogenes and major components of an emerging Hippo signaling pathway that plays important roles in regulating animal size, cell proliferation, apoptosis, tumorigenesis, stem cell renewal and differentiation, neuronal growth, and mechanotransduction in both Drosophila and mammals (8) (9) (10) (11) (12) . In this novel Author Manuscript Published OnlineFirst on May 8, 2014 ; DOI: 10.1158/0008-5472.CAN- pathway, mammalian homologs of Drosophila Hippo, Mst1 and Mst2, phosphorylate and activate tumor suppressors and kinases LATS1 and LATS2, which in turn inactivate YAP and TAZ by phosphorylating multiple sites (5 sites for YAP and 4 sites for TAZ) with consensus sequence of HxH/R/KxxS/T (H, histine; x, any amino acid; R, arginine; K, lysine; S, serine; T, threonine)(Mst1/2→LATS1/2→YAP/TAZ). These core components also interact with many upstream (e.g. NF2, RASFF1A, FAT4, etc) and downstream (CTGF, Cyr61, BMP4, etc) cellular genes, forming a complex Hippo signaling pathway. Recently, we and others have identified YAP and TAZ as important players in response of breast cancer cells to apoptosis induced by antitubulin drug Taxol (13, 14) . It has been shown that over-expression of YAP or TAZ in MCF10A mammary cells causes transformation, epithelial-mesenchymal-transition (EMT) and resistance to Taxol, whereas knockdown of TAZ in MDA-MD231 breast cancer cells sensitize these cells to Taxol (14) . However, whether YAP and TAZ overexpression causes resistance of cancer cells to other antitubulin drugs is unclear. In addition, the upstream signaling pathways or genes modulating YAP/TAZ in response to Taxol remains to be identified. In this study, we have discovered that YAP is specifically phosphorylated by Cdk1/Cyclin B kinase after antitubulin drug treatment independent of the upstream Hippo signaling pathway. We have provided strong evidence that phosphorylation of YAP by Cdk1/Cyclin B inhibits YAP-induced resistance of cancer cells to antitubulin drug treatment.
Research. 
Materials and Methods
Plasmid construction and site-directed mutagenesis. Plasmid construction and sitedirected mutagenesis were performed as described (15) .
Cell culture and treatments of cells by chemotherapeutic drugs, kinase inhibitors, and anoikis. Cell culture was as described (15) . HeLa cells were treated with antitubulin drugs (Supplementary Table S1 ) for various times, followed by protein extraction and western blot. For dose-dependent YAP phosphorylation, HeLa cells were treated with increasing concentration (0, 0.1, 0.5, 1, 5, 10, 50, 100, and 500 nM) of Taxol for 24 h, followed by protein extraction and western blot analysis. For kinase inhibitor treatments, HeLa cells were pre-treated with inhibitors for CDK, JNK, p38, GSK, MEK, DYRK, and mTOR (see Supplementary Table S1 for details) for 2 h, followed by treatment with these inhibitors for 22 h in the presence of 100 nM Taxol.
To test whether YAP phosphorylation is due to loss of anchorage of cells after antitubulin drug treatment, HeLa cells were plated onto a 60 mm plate coated with poly-HEMA (20mg/ml, Sigma) and incubated at 37 0 C for 24 h. The floating cells were then collected for protein extraction and western blot analysis. Lentivirus production, infection, and establishment of stable cell lines overexpressing or knocking down cellular genes. Lentiviral production, titration, and infection of overexpressing and short hairpin RNA (shRNA) constructs are as described (15) 
RNA extraction and quantitative reverse transcriptase PCR (qRT-PCR). RNA extraction
and qRT-PCR were as described (15) .
Antibodies, western blot, co-immunoprecipitation (Co-IP), immunostaining. The antibodies used in this study were purchased and used as listed in Supplementary Table S3 .
Rabbit anti-phospho-YAP-S367 polyclonal antibody was produced by injection of conjugated phospho-peptide (KQNPVSpSPGMSQ) into rabbit (Cocalico). Antibody was purified from antiserum using protein A beads. Protein extraction and western blot, Co-IP, and immunostaining were as described previously (15) . PAGE and stained with commassie blue. The phosphorylated YAP band was cut and identification of YAP and phosphorylated YAP peptides were performed as described (16) .
GST Fusion protein production and in vitro kinase assay ⎯GST fusion protein production and purification and in vitro kinase assays are as described (15) . Cdk1/Cyclin B active kinase was purchased from New England Biolabs. The wild-type peptide containing S128 (PQHVRAHS 128 SP) and its mutants (S128V;PQHVRAHS 128 VP) were purchased from GL Biochem (Shanghai, China).
Analysis of apoptosis by trypan blue exclusion analysis. Analysis of cell death/apoptosis by trypan blue exclusion assay was performed as described previously (14) .
Research. (Fig. 1A-B) . Besides band-shift, levels of TAZ rather than YAP were gradually decreased with time after Taxol treatment (Fig. 1A) . The band-shifts of both YAP and TAZ can be reversed after treatment of protein lysates from Taxol-treated HeLa cells with calf intestine phosphatase (CIP) (Fig. 1C) , suggesting that the band-shifts of YAP and TAZ after Taxol treatment are due to phosphorylation. To further examine whether YAP and TAZ changes are specific for Taxol drug, we examined the status of YAP and TAZ after treatment of HeLa cells with a wide variety of chemotherapeutic drugs. YAP phosphorylation is only detected in antitubulin drug-treated cells, which specifically caused reduced pCdk1, whereas TAZ phosphorylation/degradation was found in cells treated by almost all of the drugs, as indicated by increased apoptotic marker cPARP (Fig. 1D) . These results clearly demonstrated that YAP is specifically phosphorylated during mitotic arrest and apoptosis induced by antitubulin drugs in HeLa cells. To further explore whether YAP phosphorylation is dependent of drug dose, we treated HeLa cells with increasing concentration of Taxol. As expected, increasing YAP phosphorylation was detected with the increase of Taxol drug concentration, which is correlated with increasing levels of cPARP and decreasing levels of pCdk1 ( Phosphorylation of YAP is Hippo-independent. Next, we examined the expression of other Hippo core components and kinases Mst1, Mst2, LATS1 and LATS2. Except for LATS2, phosphorylation of Mst1/2 and LATS1 (pLATS1), which normally activate their kinase activity, is significantly increased ( Fig. 2A) . Since our previous studies showed that LATS1 inactivates YAP by phosphorylating 5 sites(15), we examined whether increased phosphorylation/activity of LATS1 is responsible for YAP phosphorylation after Taxol treatment by testing the levels of phosphorylated S127 (pS127) of YAP using anti-phospho-YAP-S127 antibody. Surprisingly, after Taxol treatment, the levels of YAP-p127 gradually decreased after Taxol treatment (Fig. 2B ).
Since LATS1/2 can phosphorylate YAP at 5 sites (15, 18) , it is possible that LATS1 may 
Identification of YAP phosphorylation sites.
To identify the kinase (s) phosphorylating YAP, we first attempted to map the YAP phosphorylation sites. Immunoprecipitated YAP from protein lysate extracted from Taxol-treated HeLa cells was subjected to mass-spectrometric identification of phospho-peptides. Four YAP phosphorylation sites including S128, S138, S289, and S367 were identified and all of these sites contain a "SP" motif ( Fig. 3A; Supplementary Fig.   S1 ). To confirm these potential phosphorylation sites, we constructed plasmids expressing various deletions and mutations of YAP ( Fig. 3B-C ) and transfected them into HeLa cells.
Mutations of both S128 and S138 into alanines (A, S128A/S138A) rather than a single mutation alone (S128A or S138A) abolish Taxol-induced YAP1-150-HA phosphorylation ( 3C, upper panel). While mutation of S289 or S367 alone (S289A or S367A) only has minor effect, mutation of both sites (S289A/S367A) dramatically decreases YAP203-400-HA phosphorylation. Since S289A/S367A double mutants were unable to completely abolish YAP203-400-HA phosphorylation, it is possible that another phosphorylation site not identified by mass-spectrometry may exist. By scanning YAP sequence, we identified another potential phosphorylation site, S217, which also contains "SP" motif within YAP203-400 sequence (Fig.   3B ). Triple mutation S217A/S289A/S367A completely abolishes YAP203-400 phosphorylation (Fig. 3C , middle panel). Consistent with mass-spectrometry analysis, mutation of S367 (S367A) rather than T412 (T412A), which also contains a "TP" motif, completely abolishes the phosphorylation of YAP300-504-HA. Together, through YAP deletion/mutation analysis, we have identified 5 novel YAP sites (YAP2L, a longer isoform of YAP, is used in the present study.
Refer to Supplementary Table S4 for corresponding positions in other YAP isoforms) that are significantly phosphorylated after Taxol treatment. We have further tested these 5 phosphorylation sites individually or in combination using full-length YAP. Mutation of only S367 rather than other 4 phosphorylation sites significantly but not completely reverses YAP-HA phosphorylation and band-shift, whereas mutation of all of 5 phosphorylation sites (5SA-TX) completely abolishes YAP phosphorylation after Taxol treatment (Fig. 3D) . To further confirm this result in vivo, we raised antibody against the major YAP phosphorylation site, S367. The purified anti-pS367-YAP antibody specifically recognizes phosphorylated wild-type (WT) YAP rather than YAP-S367A with S367 mutation (Fig. 3E) . YAP phosphorylation on S367 (pS367) is significantly increased in floating apoptotic rather than adherent live HeLa cells after Taxol treatment (Fig. 3F, Fig.1A ). In addition, we found that YAP-pS367 is significantly increased in Sk-BR3 cells rather than Taxol-resistant SK-BR3-TR cells after Taxol treatment (Fig. 3G) 
summary, we have successfully identified 5 "SP" motif-containing phosphorylation sites that are responsible for YAP phosphorylation/band-shift after Taxol treatment.
Identification of Cdk1 as a novel upstream kinase phosphorylating YAP after Taxol treatment. Since all of the 5 YAP phosphorylation sites contain a "SP" motif, we used PhosphoNet Kinase Predictor program to predict potential kinase(s) phosphorylating these motifs.
Seven potential kinases with high prediction score were selected as candidate kinases. By using inhibitors for each specific kinase (Supplementary Table S1), we found that inhibition of JNK or CDK kinase completely abolishes YAP phosphorylation after Taxol treatment (Fig. 4A ). Since inhibitors sometimes have non-specific activity, we directly knocked down both JNK1 and JNK2, two major JNK family members, using Doxocycline (Dox)-inducible shJNK1 and shJNK2. As shown in Fig. 4B and 4C , YAP was still phosphorylated after knockdown of both JNK1 and JNK2 (both JNK1 and JNK2 have two isoforms/bands), suggesting that JNK is not the kinase responsible for YAP phosphorylation. Supporting our unexpected data, previous studies showed that the widely used "JNK" inhibitor used in our study, SP600125, can in fact inhibit Cdk kinase non-specifically (19) . Since Cdk inhibitor also abolishes YAP phosphorylation (Fig. 4A) , it is possible that Cdk kinase, specifically Cdk1/Cyclin B, a kinase complex well-known to be involved in Taxol-induced mitotic arrest and apoptosis (20, 21) , may be essential for YAP phosphorylation. We first used several general Cdk inhibitors (ROS, Pur A, OLO II) and a Cdk1-specific inhibitor (RO-3366) to test whether they can block Taxol-induced phosphorylation.
Significantly, treatment of HeLa cells with all of these inhibitors completely abolishes Taxolinduced YAP phosphorylation (Fig. 4D) . Second, to eliminate the possibility of non-specific effects caused by Cdk1 inhibitors, we transiently knock down Cdk1 by siCdk1 or Dox-inducible shCdk1 alone or in combination. Surprisingly, although Cdk1 was knocked down significantly 
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by siCdk1 or shCdk1, YAP was still partially phosphorylated, suggesting that residual Cdk1 may still be able to phosphorylate YAP. However, Cdk1 knockdown by combined effect of siCdk1 and shCdk1 plus Dox can completely abolished Taxo-induced YAP phosphorylation (Fig. 4E) .
Similarly, inactivation of Cdk1/Cyclin B kinase complex by knocking down Cyclin B with siCyclin B also abolishes Taxol-induced YAP phosphorylation (Fig. 4F) . Our in vitro kinase assays also showed that purified Cdk1/Cyclin B kinase can directly phosphorylate purified YAP-GST rather than GST control in vitro (Fig. 4G, left and center panel) . This result was further confirmed by western blot analysis of the same blot using anti-phospho-YAP-S367 antibody (Fig.   4G , right panel) and in vitro peptide kinase assay in which wild-type containing S128 site rather than its mutant S128V peptide was significantly phosphorylated by Cdk1/Cyclin B in vitro (Fig.   4H) . Altogether, our studies clearly demonstrated that Cdk1 is indeed the critical kinase phosphorylating YAP during antitubulin drug response. Next, we would like to know whether Cdk1 is also responsible for TAZ phosphorylation. Although only S128 in YAP is conserved in TAZ, there are other 5 potential "SP" or "TP" sites in TAZ that could be phosphorylated by Cdk1 Fig. S2A ). In addition, mutation of all potential Cdk1 phosphorylation sites containing "SP" or "TP" motif in TAZ (TAZ-6SA) also significantly block Taxol-induced TAZ phosphorylation/degradation ( Supplementary Fig. S2B ), suggesting that TAZ may be also phosphorylated by Cdk1.
Effect of YAP phosphorylation on its transactivating activity. We have previously shown that interaction and activation of transcription factor TEAD4 is essential for TAZ-induced Taxol
Research. (14) . To examine the effect of YAP phosphorylation on its function, we have performed Co-IP analysis of YAP and TEAD4 in the absence and presence of Taxol treatment ( Fig. 5A-5B ). In the absence of Taxol treatment, HA-tagged YAP strongly interacts with FLAG-tagged TEAD4 in vivo in HeLa cells. Although treatment of HeLa cells has no effect on the levels of both YAP-HA and TEAD4-FLAG (for better quantification, high percentage of SDS-PAGE was run for western blot to eliminate YAP-HA band-shift in Taxol-treated protein lysate), Taxol treatment significantly reduced the interaction of YAP-HA with TEAD4-FLAG (Fig. 5A) . However, this disruption of YAP-TEAD4 interaction was rescued after inactivation of Cdk1 by Cyclin B knockdown ( Supplementary Fig. S3A ). In addition, Taxol treatment was unable to disrupt interaction between phosphorylation-deficient YAP-5SA-TX and TEAD4
( Supplementary Fig. S3B ), suggesting that phosphorylation of YAP after Taxol treatment is essential for its reduced interaction with TEAD after Taxol treatment. To directly confirm YAP phosphorylation reduces its interaction with TEAD4, we also constructed YAP mutants that change all 5 serine phosphorylation sites to either "A"s (YAP-5SA-TX, inactivating mutation) or aspartic acid (YAP-5SD-TX, mimicking phosphorylation). YAP-5SA-TX is used to distinguish it from the LATS phosphorylation mutant YAP-5SA (Fig. 2C) . Consistent with Taxol treatment experiment, although similar levels of wild-type (YAP-HA) and mutant YAP were detected in cells, interaction of TEAD4-FLAG with YAP-5SD-TX-HA is significantly weaker than that with YAP-HA or YAP-5SA-TX-HA (Fig. 5B) , suggesting that Taxol-induced YAP phosphorylation may reduce its ability to interact with and activate transcription factor TEAD. To confirm that reduced interaction of YAP with TEAD after phosphorylation causes its decreased co- (Fig.   5D ). Although similar level of YAP and its mutants were expressed (Fig. 5C) , significantly reduced levels of CTGF or Cyr61 mRNA were detected in YAP-5SD-TX-MCF10A (Fig. 5D) .
Together, these experiments clearly demonstrate that phosphorylation of YAP by Cdk1 after Taxol treatment reduced its ability to interact with transcription factor TEAD and trans-activate its downstream genes important for Taxol response.
Effect of YAP phosphorylation on its ability to inhibit antitubulin drug-induced apoptosis.
Previous studies have shown that over-expression of YAP inhibits Taxol-induced apoptosis in MCF10A cells (13) . To test whether YAP phosphorylation has any effect on its ability to reduce Taxol-induced apoptosis, we have established MCF10A cells stably expressing WPI vector, YAP-WT, YAP-5SA-TX, or YAP-5SD-TX (Fig. 5C ). Most interestingly, although both YAP-WT and YAP-5SA-TX cause morphological changes from epithelial (normal cell-cell contact, high epithelial marker E-cadherin, and low mesenchymal marker Vimentin) to mesenchymal phenotype (loss of cell-cell contact, reduced E-cadherin, and increased Vimentin) as previously observed (13), YAP-5SD-TX mutant fails to cause significant morphological changes (Fig. 6A-6C ). Most significantly, consistent to morphological changes, analysis of apoptosis by western blot analysis of cPARP and trypan blue exclusion assay all showed that compared to wild-type and YAP-5SA-TX, YAP-5SD-TX has significant decreased ability to inhibit apoptosis induced by both Taxol and Vinblastine (Fig. 6D-6E ), two commonly used S4 ), suggesting that YAP is only phosphorylated and inactivated during antitubulin drug response.
Discussion
Although tremendous progress has been made toward our understanding of the roles of the Hippo pathway in tumorigenesis, size control, and stem cell renewal and differentiation (8) (9) (10) (11) , its function in chemotherapeutic drug response is largely unknown (23) . We and others have recently provided initial evidence that the core components of the Hippo pathway, LATS1/2, YAP, and TAZ, may be involved in the response of cancer cells to chemotherapeutic drugs such as Taxol (14, (24) (25) (26) . However, the upstream signaling pathway(s) or gene(s) transducing signals from drug treatment to the Hippo pathway remains elusive. In this study, we have shown for the first time that Cdk1 is a novel kinase responsible for inactivation of YAP during antitubulin druginduced apoptosis. We found that YAP is specifically phosphorylated in floating apoptotic cells rather than adherent survival cells after antitubulin drug treatment (Fig. 1A-1B) . Significantly, we have shown that activated Cdk1 can directly phosphorylate YAP both in vitro and in vivo, which subsequently caused reduced co-transactivating and anti-apoptotic activity of YAP.
Although many genes have been identified to affect the sensitivity of cancer cells to antitubulin chemotherapeutics and it is well known that aberrant activation of Cdk1/Cyclin B is critical for antitubulin drug-induced apoptosis (20, 21) , only a few genes are identified to be directly phosphorylated and regulated by Cdk1/Cyclin B (21, 27) . Therefore, our studies provide the first biological evidence that the Hippo core component YAP is a sensor for Cdk1 kinase activity and a critical link coupling Cdk1 activation to antitubulin drug-induced apoptosis.
Although Hippo pathway (Mst1/2-LATS1/2-YAP/TAZ) has been shown to play important roles in many biological processes, mounting evidence suggested that Hippo-independent pathways upstream of YAP/TAZ might be also important. For example, it was recently shown that YAP and TAZ are activated by cell shape, cytoskeletal and mechanical cues independent of its upstream kinases Mst1/2 and LATS1/2 (11, 28, 29) . Therefore, it has been suggested that YAP and TAZ are central players of the Hippo pathway and different stimuli may induce various biological changes by regulating YAP/TAZ through multiple signaling pathways (30) . In this study, we have identified another novel Hippo-independent pathway modulating YAP. In this pathway, antitubulin drugs induce microtubule tension by causing increased microtubule polymerization or depolymerization(2, 21), which subsequently causes increased Cyclin B levels ( Fig. 4F) and activation of Cdk1 kinase (Fig. 1D) . Activated Cdk1 in turn phosphorylates YAP on 5 sites (S128, S138, S217, S289, and S367), which inactivate YAP function as a transcriptional co-activator and an anti-apoptotic protein, leading to apoptotic cell death.
Although TAZ is a paralog of YAP and has over-lapping function in various biological functions (8) , it is still unclear why YAP and TAZ have different response to antitubulin drug treatment. As shown in Fig. 1D , while YAP is phosphorylated only in mitotic arrested and apoptotic cells as indicated by reduced pCdk1 and increased cPARP, TAZ is phosphorylated and degraded in all apoptotic cells induced by almost all of the chemotherapeutics used independent of mitotic arrest, suggesting that YAP and TAZ may function differently in response to Taxol. In addition, we also found that TAZ phosphorylation/degradation is significantly blocked in Cdk1-knockdown HeLa cells after Taxol treatment (Supplementary Fig. S2A ). These findings suggest that TAZ may be involved in apoptosis in Cdk1-dependent and/or Cdk1-independent pathways. of YAP phosphorylation sites under physiological conditions (31) . Since Cdk1/Cyclin B kinase complex is also activated during G 2 /M phase of the cell cycle, it is possible that YAP is phosphorylated by Cdk1 during mitosis. It will be very interesting to further study whether YAP is differentially phosphorylated during mitosis and under microtubule damage induced by antitubulin drugs. Moreover, we have found that phosphorylation of YAP abolishes its ability to induce morphological changes such as EMT indicated by reduced E-cadherin and enhanced Vimentin (Fig. 6A-6C ). Since there is a strong link between EMT and drug resistance (32) , it is possible that phosphorylation and inactivation of YAP by Cdk1 may compromise its ability to trans-activate another transcription factor that suppresses E-cadherin and induces EMT.
Moreover, since EMT plays important roles in stem cell renewal, cell migration, anoikis, invasion and metastasis (33, 34) , it will be also interesting to further explore how phosphorylation of YAP under physiological condition regulates these important biological processes.
In this study, we have established YAP as an anti-apoptotic protein important for antitubulin drug resistance. We have shown that over-expression of YAP-WT and its phosphorylation mutant YAP-5SA-TX rather than its phosphomimic mutant YAP-5SD-TX causes resistance of MCF10A mammary cells to both Taxol and Vinblastine (Fig. 6D-6E and their counterparts, we have found that YAP is not phosphorylated after Taxol treatment in drug-resistant SK-BR3 cells (Fig. 1H and 3G Table S1 ). B. C.
Knockdown of JNK1/2 has no effect on YAP phosphorylation. shJNK1 and shJNK2 cloned in Dox-inducible vector pTRIPZ were stably expressed in HeLa cells. Cells were incubated in the absence (-) or presence (+) of 1 μg/ml Dox for 5 days, followed by protein extraction and western blot analysis of JNK1 and JNK2 (B). HeLa-shJNK1/2 cells were also treated with Dox for 5 days, followed by untreated (-) 
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Ponceau S (left panel) and exposed to film (middle panel). The same membrane was later subjected to western blot analysis using anti-pS367-YAP antibody (right panel). H. Peptide kinase assay. In vitro kinase assays were carried out using 20U of Cdk1/Cyclin B. 
